Cubist Names Dr. Patrick Vink Chief Operating Officer
November 05 2014 - 7:30AM
Business Wire
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that
Patrick Vink, M.D., M.B.A., currently Senior Vice President and
General Manager of Cubist’s International Business, has been
promoted to Executive Vice President and Chief Operating Officer,
effective January 1, 2015.
Patrick Vink, Cubist Pharmaceuticals
(Photo: Business Wire)
In his new role, Dr. Vink will oversee all global commercial,
manufacturing, technical operations, international business
operations, and alliance management. Dr. Vink will report into
Robert J. Perez, Cubist’s current President and COO who, as
announced on October 20, will become the Company’s Chief Executive
Officer effective January 1, 2015.
“Patrick is a distinguished and trusted biotechnology executive
who has demonstrated his leadership and expertise in his work to
build Cubist’s international operations,” said Perez. “I have
tremendous confidence in Patrick’s ability to build on Cubist’s
momentum and drive our continued global growth with
industry-leading operational practices. His insights into
international markets and close ties to our key customers in the
U.S. and abroad, will be critical as we continue to enhance our
leadership position and work towards achieving our Building Blocks
of Growth while generating sustained shareholder value.”
“We have a strong, talented team in place, and I am excited by
the opportunities ahead,” said Dr. Vink. “As Cubist continues to
focus on important upcoming milestones, including the U.S. Food and
Drug Administration action date in December for our potential
blockbuster ZERBAXA and 2015 product launches in international
markets, I am confident in our ability to execute on our goals and
expand our leadership in the research, development, and
commercialization of potentially life-saving therapies for patients
worldwide.”
Since joining Cubist in 2012, Dr. Vink led the building of the
Company’s international team and business operations and oversaw
the Company’s successful submissions of Marketing Authorization
Applications to the European Medicines Agency for two
investigational antibiotics. European Commission decision on both
is expected in 2015.
Prior to joining Cubist, Dr. Vink served as Senior Vice
President, Global Head of Hospital Business and Global Head of
Biologics for Mylan Inc. In this role, Dr. Vink coordinated all
hospital business of the company. He joined Mylan in 2008, and
established the company’s operations in Switzerland, which was the
basis of a number of global functions. Dr. Vink was also
responsible for the company’s biosimilars market entry. Prior to
Mylan, Dr. Vink held several leadership positions across the
industry, including Head of Business Franchise Biopharmaceuticals
for Novartis Sandoz; Director, Central Europe and VP International
Sales for Biogen; and Head of Worldwide Marketing, Cardiovascular
and Thrombosis for Sanofi-Synthelabo.
About CubistCubist Pharmaceuticals, Inc. is a global
biopharmaceutical company focused on the research, development, and
commercialization of pharmaceutical products that address
significant unmet medical needs in the acute care environment.
Cubist is headquartered in Lexington, Massachusetts, with an
international headquarters located in Zurich, Switzerland.
Additional information can be found at Cubist’s web site at
www.cubist.com. Also, connect with Cubist on Twitter
@cubistbiopharma and @cubistcareers, LinkedIn, or YouTube.
Forward Looking StatementsThis press release contains
forward-looking statements. Any statements contained herein which
do not describe historical facts, including but not limited to,
statements regarding: the expected appointment of our new COO and
our new CEO; ZERBAXA’s potential to achieve blockbuster status; the
FDA’s targeted action date for ZERBAXA; the expected timing for
decisions from the European Commission on our Marketing
Authorization Applications for two of our investigational
antibiotics; the expected timing for our product launches in
international markets; our Building Blocks of Growth five-year
goals through 2017; and our intent to continue growing Cubist, are
forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those
discussed in such forward-looking statements. Such risks and
uncertainties include, among others: the risk that the planned
leadership transition does not occur in the manner or on the time
frame that we currently expect; the risk that the FDA, European
Commission and other regulatory authorities may not approve on a
timely basis or at all our planned new products; risks related to
our ability to achieve our financial and business objectives,
including as a result of our ability to continue to grow revenues
from the sale of our commercial products, generic and other
competition, manufacturing issues, our ability to successfully
develop, gain marketing approval for and launch our product
candidates as currently planned, and our ability to discover,
in-license or acquire new products and product candidates; our
ability to successfully commercialize our products; competitive
risks from current and future therapeutic alternatives to our
products; our ability to obtain, maintain and enforce intellectual
property for our products and product candidates; technical
difficulties, excessive costs or other issues relating to the
manufacture or supply of our products and product candidates,
including our ability to work with our third party contract
manufacturers that manufacture and supply our product and product
candidates; and those additional factors discussed in our most
recent Annual Report on Form 10-K and subsequent Quarterly Reports
on Form 10-Q filed with the Securities and Exchange Commission. We
caution investors not to place considerable reliance on the
forward-looking statements contained in this press release. These
forward-looking statements speak only as of the date of this
document, and we undertake no obligation to update or revise any of
these statements.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20141105005162/en/
Cubist Pharmaceuticals, Inc.MEDIA:Julie DiCarlo,
781-860-8063Senior Director, Corporate
Communicationsjulie.dicarlo@cubist.comorINVESTORS:Eileen C.
McIntyre, 781-860-8533Vice President, Investor
Relationseileen.mcintyre@cubist.com